Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14

Key Points

• Analysts remain broadly bullish: Inventiva has a consensus “Buy” rating from 10 analysts, with an average 12-month price target of $15.14.
• Institutional ownership is growing: Hedge funds and other institutional investors own 19.06% of the company after several firms established new positions.
• The investment case remains high risk: Inventiva is strengthening its cash position ahead of Phase 3 NATiV3 results, but a recent earnings and revenue miss, a 25.5% monthly stock decline, and dependence on clinical execution weigh on the outlook.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $15.14.

IVA has been the subject of a number of research reports. Cantor Fitzgerald began coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an "overweight" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Guggenheim upped their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, September 15th. Finally, Piper Sandler restated an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th.

Institutional Investors Weigh In On Inventiva

Institutional investors have recently bought and sold shares of the stock. NEXTBio Capital Management LP purchased a new position in Inventiva in the 4th quarter worth approximately $6,039,000. Propel Bio Management LLC purchased a new stake in shares of Inventiva during the fourth quarter valued at approximately $4,650,000. Eventide Asset Management LLC purchased a new stake in shares of Inventiva during the fourth quarter valued at approximately $1,155,000. Seven Fleet Capital Management LP bought a new position in shares of Inventiva in the first quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Inventiva in the fourth quarter worth approximately $603,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Inventiva News

Here are the key news stories impacting Inventiva this week:

• Positive Sentiment: Inventiva reported that its first-half net loss narrowed, a sign of improved cost control. Management also highlighted ongoing progress and an active second half centered on its clinical programs. Inventiva H1 Loss Drops
• Positive Sentiment: The company strengthened its cash position to approximately €166.1 million, improving financial flexibility ahead of the Phase 3 NATiV3 results and reducing near-term funding concerns. Inventiva strengthens cash position
• Positive Sentiment: Several market views remain favorable, reflecting optimism surrounding Inventiva’s pipeline and the potential importance of the NATiV3 clinical readout. Inventiva receives several positive opinions
• Neutral Sentiment: The Q2 earnings call and first-half update emphasized upcoming catalysts and the company’s development plans, but the investment case remains highly dependent on clinical execution and NATiV3 results. Inventiva Q2 2026 earnings call transcript
• Negative Sentiment: Inventiva reported an adjusted loss of $0.28 per share, worse than the expected $0.20 loss, while revenue of $0.02 million was far below the $2.88 million consensus estimate. The earnings miss likely contributed to selling pressure. Inventiva earnings results
• Negative Sentiment: Technical selling has intensified after a 25.5% monthly decline. Investors are watching the €2.77 support level; a break below it could increase downside momentum. Inventiva stock technical analysis

Inventiva Trading Up 12.2%

NASDAQ:IVA opened at $3.69 on Thursday. The business has a 50 day moving average of $4.37 and a 200 day moving average of $4.69. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.16 and a current ratio of 3.81. Inventiva has a 1-year low of $3.11 and a 1-year high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million for the quarter. As a group, research analysts anticipate that Inventiva will post -0.81 earnings per share for the current fiscal year.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.